Evaxion Biotech A/S is a clinical-stage AI-immunology™ platform company decoding the human immune system to discover and develop novel immunotherapies to treat cancer and infectious diseases.
Evaxion Biotech has raised €38M across 1 funding round from 1 investor, most recently a round in Jun 2022. Based in Copenhagen, Denmark; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-06-10 | Other | €38M |
| Lincoln Park Capital Fund |
| View deal → |
